Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

SINGAPORE - Media OutReach Newswire - 22 December 2023 - Novo Nordisk Pharma (Thailand) Ltd. has emerged triumphant by securing three prestigious accolades at the Asia Pacific Enterprise Awards (APEA) ...

Eli Lilly and Novo Nordisk didn't quite beat expectations with their recent earnings. Their weight loss drugs slightly underperformed. That underperformance may portend more difficulty.

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

After massive market cap growth for Eli Lilly and Novo Nordisk since the start of the decade, investor enthusiasm dimmed for the two most valuable companies in the industry in the third quarter.

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

1 Day NVO 1.88% DJIA 0.68% S&P 500 -0.03% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Novo Nordisk is working on a new obesity drug that could help patients shed more than any other weight-loss drug on the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...